GlassScriptPhysician profile
Michael Hung Hsu
NPI 1962721530
$10,150.48
in general payments reported to CMS, 2019-2025
41 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $488 · 2021: $765 · 2022: $1,882 · 2023: $2,069 · 2024: $2,026 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,058.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,298.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,963.24 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $998.95 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $852.33 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Qol Medical, LLC | $727.25 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $399.68 | 2022-2025 | |
| Pfizer INC. | $290.08 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $223.12 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $216.69 | 2019-2025 | |
| Daiichi Sankyo INC. | $210.51 | 2019-2025 | Injectafer |
| Lilly USA, LLC | $186.52 | 2023-2025 | Omvoh |
| Celgene Corporation | $177.54 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $161.91 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $160.46 | 2020-2024 | Embold Fibered |
| Ardelyx, INC. | $145.58 | 2023-2025 | Ibsrela |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.